1 Rare Neurodegenerative Disease Treatment Market Overview 1.1 Rare Neurodegenerative Disease Treatment Product Overview 1.2 Rare Neurodegenerative Disease Treatment Market Segment by Type 1.2.1 Neurotransmitter Agents 1.2.2 Neuroprotective Agents 1.2.3 Biologics 1.2.4 Others 1.3 Global Rare Neurodegenerative Disease Treatment Market Size by Type 1.3.1 Global Rare Neurodegenerative Disease Treatment Market Size Overview by Type (2016-2027) 1.3.2 Global Rare Neurodegenerative Disease Treatment Historic Market Size Review by Type (2016-2021) 1.3.2.1 Global Rare Neurodegenerative Disease Treatment Sales Breakdown in Volume by Type (2016-2021) 1.3.2.2 Global Rare Neurodegenerative Disease Treatment Sales Breakdown in Value by Type (2016-2021) 1.3.2.3 Global Rare Neurodegenerative Disease Treatment Average Selling Price (ASP) by Type (2016-2021) 1.3.3 Global Rare Neurodegenerative Disease Treatment Forecasted Market Size by Type (2022-2027) 1.3.3.1 Global Rare Neurodegenerative Disease Treatment Sales Breakdown in Volume by Type (2022-2027) 1.3.3.2 Global Rare Neurodegenerative Disease Treatment Sales Breakdown in Value by Type (2022-2027) 1.3.3.3 Global Rare Neurodegenerative Disease Treatment Average Selling Price (ASP) by Type (2022-2027) 1.4 Key Regions Market Size Segment by Type 1.4.1 North America Rare Neurodegenerative Disease Treatment Sales Breakdown by Type (2016-2021) 1.4.2 Europe Rare Neurodegenerative Disease Treatment Sales Breakdown by Type (2016-2021) 1.4.3 Asia-Pacific Rare Neurodegenerative Disease Treatment Sales Breakdown by Type (2016-2021) 1.4.4 Latin America Rare Neurodegenerative Disease Treatment Sales Breakdown by Type (2016-2021) 1.4.5 Middle East and Africa Rare Neurodegenerative Disease Treatment Sales Breakdown by Type (2016-2021) 2 Global Rare Neurodegenerative Disease Treatment Market Competition by Company 2.1 Global Top Players by Rare Neurodegenerative Disease Treatment Sales (2016-2021) 2.2 Global Top Players by Rare Neurodegenerative Disease Treatment Revenue (2016-2021) 2.3 Global Top Players Rare Neurodegenerative Disease Treatment Price (2016-2021) 2.4 Global Top Manufacturers Rare Neurodegenerative Disease Treatment Manufacturing Base Distribution, Sales Area, Product Type 2.5 Rare Neurodegenerative Disease Treatment Market Competitive Situation and Trends 2.5.1 Rare Neurodegenerative Disease Treatment Market Concentration Rate (2016-2021) 2.5.2 Global 5 and 10 Largest Manufacturers by Rare Neurodegenerative Disease Treatment Sales and Revenue in 2020 2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Rare Neurodegenerative Disease Treatment as of 2020) 2.7 Date of Key Manufacturers Enter into Rare Neurodegenerative Disease Treatment Market 2.8 Key Manufacturers Rare Neurodegenerative Disease Treatment Product Offered 2.9 Mergers & Acquisitions, Expansion 3 Rare Neurodegenerative Disease Treatment Status and Outlook by Region 3.1 Global Rare Neurodegenerative Disease Treatment Market Size and CAGR by Region: 2016 VS 2021 VS 2026 3.2 Global Rare Neurodegenerative Disease Treatment Historic Market Size by Region 3.2.1 Global Rare Neurodegenerative Disease Treatment Sales in Volume by Region (2016-2021) 3.2.2 Global Rare Neurodegenerative Disease Treatment Sales in Value by Region (2016-2021) 3.2.3 Global Rare Neurodegenerative Disease Treatment Sales (Volume & Value) Price and Gross Margin (2016-2021) 3.3 Global Rare Neurodegenerative Disease Treatment Forecasted Market Size by Region 3.3.1 Global Rare Neurodegenerative Disease Treatment Sales in Volume by Region (2022-2027) 3.3.2 Global Rare Neurodegenerative Disease Treatment Sales in Value by Region (2022-2027) 3.3.3 Global Rare Neurodegenerative Disease Treatment Sales (Volume & Value), Price and Gross Margin (2022-2027) 4 Global Rare Neurodegenerative Disease Treatment by Application 4.1 Rare Neurodegenerative Disease Treatment Market Segment by Application 4.1.1 Amyotrophic Lateral Sclerosis (ALS) 4.1.2 Attention Deficit Hyperactivity Disorder (ADHD) 4.1.3 Alzheimer’s Disease 4.1.4 Parkinson’s Disease 4.1.5 Others 4.2 Global Rare Neurodegenerative Disease Treatment Market Size by Application 4.2.1 Global Rare Neurodegenerative Disease Treatment Market Size Overview by Application (2016-2027) 4.2.2 Global Rare Neurodegenerative Disease Treatment Historic Market Size Review by Application (2016-2021) 4.2.2.1 Global Rare Neurodegenerative Disease Treatment Sales Breakdown in Volume, by Application (2016-2021) 4.2.2.2 Global Rare Neurodegenerative Disease Treatment Sales Breakdown in Value, by Application (2016-2021) 4.2.2.3 Global Rare Neurodegenerative Disease Treatment Average Selling Price (ASP) by Application (2016-2021) 4.2.3 Global Rare Neurodegenerative Disease Treatment Forecasted Market Size by Application (2022-2027) 4.2.3.1 Global Rare Neurodegenerative Disease Treatment Sales Breakdown in Volume, by Application (2022-2027) 4.2.3.2 Global Rare Neurodegenerative Disease Treatment Sales Breakdown in Value, by Application (2022-2027) 4.2.3.3 Global Rare Neurodegenerative Disease Treatment Average Selling Price (ASP) by Application (2022-2027) 4.3 Key Regions Market Size Segment by Application 4.3.1 North America Rare Neurodegenerative Disease Treatment Sales Breakdown by Application (2016-2021) 4.3.2 Europe Rare Neurodegenerative Disease Treatment Sales Breakdown by Application (2016-2021) 4.3.3 Asia-Pacific Rare Neurodegenerative Disease Treatment Sales Breakdown by Application (2016-2021) 4.3.4 Latin America Rare Neurodegenerative Disease Treatment Sales Breakdown by Application (2016-2021) 4.3.5 Middle East and Africa Rare Neurodegenerative Disease Treatment Sales Breakdown by Application (2016-2021) 5 North America Rare Neurodegenerative Disease Treatment by Country 5.1 North America Rare Neurodegenerative Disease Treatment Historic Market Size by Country 5.1.1 North America Rare Neurodegenerative Disease Treatment Sales in Volume by Country (2016-2021) 5.1.2 North America Rare Neurodegenerative Disease Treatment Sales in Value by Country (2016-2021) 5.2 North America Rare Neurodegenerative Disease Treatment Forecasted Market Size by Country 5.2.1 North America Rare Neurodegenerative Disease Treatment Sales in Volume by Country (2022-2027) 5.2.2 North America Rare Neurodegenerative Disease Treatment Sales in Value by Country (2022-2027) 6 Europe Rare Neurodegenerative Disease Treatment by Country 6.1 Europe Rare Neurodegenerative Disease Treatment Historic Market Size by Country 6.1.1 Europe Rare Neurodegenerative Disease Treatment Sales in Volume by Country (2016-2021) 6.1.2 Europe Rare Neurodegenerative Disease Treatment Sales in Value by Country (2016-2021) 6.2 Europe Rare Neurodegenerative Disease Treatment Forecasted Market Size by Country 6.2.1 Europe Rare Neurodegenerative Disease Treatment Sales in Volume by Country (2022-2027) 6.2.2 Europe Rare Neurodegenerative Disease Treatment Sales in Value by Country (2022-2027) 7 Asia-Pacific Rare Neurodegenerative Disease Treatment by Region 7.1 Asia-Pacific Rare Neurodegenerative Disease Treatment Historic Market Size by Region 7.1.1 Asia-Pacific Rare Neurodegenerative Disease Treatment Sales in Volume by Region (2016-2021) 7.1.2 Asia-Pacific Rare Neurodegenerative Disease Treatment Sales in Value by Region (2016-2021) 7.2 Asia-Pacific Rare Neurodegenerative Disease Treatment Forecasted Market Size by Region 7.2.1 Asia-Pacific Rare Neurodegenerative Disease Treatment Sales in Volume by Region (2022-2027) 7.2.2 Asia-Pacific Rare Neurodegenerative Disease Treatment Sales in Value by Region (2022-2027) 8 Latin America Rare Neurodegenerative Disease Treatment by Country 8.1 Latin America Rare Neurodegenerative Disease Treatment Historic Market Size by Country 8.1.1 Latin America Rare Neurodegenerative Disease Treatment Sales in Volume by Country (2016-2021) 8.1.2 Latin America Rare Neurodegenerative Disease Treatment Sales in Value by Country (2016-2021) 8.2 Latin America Rare Neurodegenerative Disease Treatment Forecasted Market Size by Country 8.2.1 Latin America Rare Neurodegenerative Disease Treatment Sales in Volume by Country (2022-2027) 8.2.2 Latin America Rare Neurodegenerative Disease Treatment Sales in Value by Country (2022-2027) 9 Middle East and Africa Rare Neurodegenerative Disease Treatment by Country 9.1 Middle East and Africa Rare Neurodegenerative Disease Treatment Historic Market Size by Country 9.1.1 Middle East and Africa Rare Neurodegenerative Disease Treatment Sales in Volume by Country (2016-2021) 9.1.2 Middle East and Africa Rare Neurodegenerative Disease Treatment Sales in Value by Country (2016-2021) 9.2 Middle East and Africa Rare Neurodegenerative Disease Treatment Forecasted Market Size by Country 9.2.1 Middle East and Africa Rare Neurodegenerative Disease Treatment Sales in Volume by Country (2022-2027) 9.2.2 Middle East and Africa Rare Neurodegenerative Disease Treatment Sales in Value by Country (2022-2027) 10 Company Profiles and Key Figures in Rare Neurodegenerative Disease Treatment Business 10.1 Bayer 10.1.1 Bayer Corporation Information 10.1.2 Bayer Introduction and Business Overview 10.1.3 Bayer Rare Neurodegenerative Disease Treatment Sales, Revenue and Gross Margin (2016-2021) 10.1.4 Bayer Rare Neurodegenerative Disease Treatment Products Offered 10.1.5 Bayer Recent Development 10.2 GlaxoSmithKline 10.2.1 GlaxoSmithKline Corporation Information 10.2.2 GlaxoSmithKline Introduction and Business Overview 10.2.3 GlaxoSmithKline Rare Neurodegenerative Disease Treatment Sales, Revenue and Gross Margin (2016-2021) 10.2.4 Bayer Rare Neurodegenerative Disease Treatment Products Offered 10.2.5 GlaxoSmithKline Recent Development 10.3 Hoffmann-La Roche 10.3.1 Hoffmann-La Roche Corporation Information 10.3.2 Hoffmann-La Roche Introduction and Business Overview 10.3.3 Hoffmann-La Roche Rare Neurodegenerative Disease Treatment Sales, Revenue and Gross Margin (2016-2021) 10.3.4 Hoffmann-La Roche Rare Neurodegenerative Disease Treatment Products Offered 10.3.5 Hoffmann-La Roche Recent Development 10.4 Allergan 10.4.1 Allergan Corporation Information 10.4.2 Allergan Introduction and Business Overview 10.4.3 Allergan Rare Neurodegenerative Disease Treatment Sales, Revenue and Gross Margin (2016-2021) 10.4.4 Allergan Rare Neurodegenerative Disease Treatment Products Offered 10.4.5 Allergan Recent Development 10.5 Merck KGaA 10.5.1 Merck KGaA Corporation Information 10.5.2 Merck KGaA Introduction and Business Overview 10.5.3 Merck KGaA Rare Neurodegenerative Disease Treatment Sales, Revenue and Gross Margin (2016-2021) 10.5.4 Merck KGaA Rare Neurodegenerative Disease Treatment Products Offered 10.5.5 Merck KGaA Recent Development 10.6 Johnson and Johnson 10.6.1 Johnson and Johnson Corporation Information 10.6.2 Johnson and Johnson Introduction and Business Overview 10.6.3 Johnson and Johnson Rare Neurodegenerative Disease Treatment Sales, Revenue and Gross Margin (2016-2021) 10.6.4 Johnson and Johnson Rare Neurodegenerative Disease Treatment Products Offered 10.6.5 Johnson and Johnson Recent Development 10.7 Pfizer 10.7.1 Pfizer Corporation Information 10.7.2 Pfizer Introduction and Business Overview 10.7.3 Pfizer Rare Neurodegenerative Disease Treatment Sales, Revenue and Gross Margin (2016-2021) 10.7.4 Pfizer Rare Neurodegenerative Disease Treatment Products Offered 10.7.5 Pfizer Recent Development 10.8 Novartis 10.8.1 Novartis Corporation Information 10.8.2 Novartis Introduction and Business Overview 10.8.3 Novartis Rare Neurodegenerative Disease Treatment Sales, Revenue and Gross Margin (2016-2021) 10.8.4 Novartis Rare Neurodegenerative Disease Treatment Products Offered 10.8.5 Novartis Recent Development 10.9 Sanofi 10.9.1 Sanofi Corporation Information 10.9.2 Sanofi Introduction and Business Overview 10.9.3 Sanofi Rare Neurodegenerative Disease Treatment Sales, Revenue and Gross Margin (2016-2021) 10.9.4 Sanofi Rare Neurodegenerative Disease Treatment Products Offered 10.9.5 Sanofi Recent Development 10.10 Teva Pharmaceuticals 10.10.1 Company Basic Information, Manufacturing Base and Competitors 10.10.2 Rare Neurodegenerative Disease Treatment Product Category, Application and Specification 10.10.3 Teva Pharmaceuticals Rare Neurodegenerative Disease Treatment Sales, Revenue, Price and Gross Margin (2016-2021) 10.10.4 Main Business Overview 10.10.5 Teva Pharmaceuticals Recent Development 11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis 11.1 Rare Neurodegenerative Disease Treatment Key Raw Materials 11.1.1 Key Raw Materials 11.1.2 Key Raw Materials Price 11.1.3 Raw Materials Key Suppliers 11.2 Manufacturing Cost Structure 11.2.1 Raw Materials 11.2.2 Labor Cost 11.2.3 Manufacturing Expenses 11.3 Rare Neurodegenerative Disease Treatment Industrial Chain Analysis 11.4 Rare Neurodegenerative Disease Treatment Market Dynamics 11.4.1 Industry Trends 11.4.2 Market Drivers 11.4.3 Market Challenges 11.4.4 Market Restraints 12 Market Strategy Analysis, Distributors 12.1 Sales Channel 12.2 Rare Neurodegenerative Disease Treatment Distributors 12.3 Rare Neurodegenerative Disease Treatment Downstream Customers 13 Research Findings and Conclusion 14 Appendix 14.1 Research Methodology 14.1.1 Methodology/Research Approach 14.1.1.1 Research Programs/Design 14.1.1.2 Market Size Estimation 14.1.1.3 Market Breakdown and Data Triangulation 14.1.2 Data Source 14.1.2.1 Secondary Sources 14.1.2.2 Primary Sources 14.2 Author Details 14.3 Disclaimer

List of Tables Table 1. Major Company of Neurotransmitter Agents Table 2. Major Company of Neuroprotective Agents Table 3. Major Company of Biologics Table 4. Major Company of Others Table 5. Global Rare Neurodegenerative Disease Treatment Sales by Type 2016 VS 2021 VS 2027 (US$ Million) Table 6. Global Rare Neurodegenerative Disease Treatment Sales by Type (2016-2021) & (K Units) Table 7. Global Rare Neurodegenerative Disease Treatment Sales Market Share in Volume by Type (2016-2021) Table 8. Global Rare Neurodegenerative Disease Treatment Sales by Type (2016-2021) & (US& Million) Table 9. Global Rare Neurodegenerative Disease Treatment Market Share in Value by Type (2016-2021) Table 10. Global Rare Neurodegenerative Disease Treatment Price by Type (2016-2021) & (US$/Unit) Table 11. Global Rare Neurodegenerative Disease Treatment Sales by Type (2022-2027) & (K Units) Table 12. Global Rare Neurodegenerative Disease Treatment Sales Market Share in Volume by Type (2022-2027) Table 13. Global Rare Neurodegenerative Disease Treatment Sales by Type (2022-2027) & (US$ Million) Table 14. Global Rare Neurodegenerative Disease Treatment Sales Market Share in Value by Type (2022-2027) Table 15. Global Rare Neurodegenerative Disease Treatment Price by Type (2022-2027) & (US$/Unit) Table 16. North America Rare Neurodegenerative Disease Treatment Sales by Type (2016-2021) & (K Units) Table 17. North America Rare Neurodegenerative Disease Treatment Sales by Type (2016-2021) & (US$ Million) Table 18. Europe Rare Neurodegenerative Disease Treatment Sales (K Units) by Type (2016-2021) Table 19. Europe Rare Neurodegenerative Disease Treatment Sales by Type (2016-2021) & (US$ Million) Table 20. Asia-Pacific Rare Neurodegenerative Disease Treatment Sales (K Units) by Type (2016-2021) Table 21. Asia-Pacific Rare Neurodegenerative Disease Treatment Sales by Type (2016-2021) & (US$ Million) Table 22. Latin America Rare Neurodegenerative Disease Treatment Sales (K Units) by Type (2016-2021) Table 23. Latin America Rare Neurodegenerative Disease Treatment Sales by Type (2016-2021) & (US$ Million) Table 24. Middle East and Africa Rare Neurodegenerative Disease Treatment Sales (K Units) by Type (2016-2021) Table 25. Middle East and Africa Rare Neurodegenerative Disease Treatment Sales by Type (2016-2021) & (US$ Million) Table 26. Global Rare Neurodegenerative Disease Treatment Sales by Company (2016-2021) & (K Units) Table 27. Global Rare Neurodegenerative Disease Treatment Sales Share by Company (2016-2021) Table 28. Global Rare Neurodegenerative Disease Treatment Revenue by Company (2016-2021) & (US$ Million) Table 29. Global Rare Neurodegenerative Disease Treatment Revenue Share by Company (2016-2021) Table 30. Global Market Rare Neurodegenerative Disease Treatment Price by Company (2016-2021) & (US$/Unit) Table 31. Global Rare Neurodegenerative Disease Treatment Top Manufacturers Manufacturing Base Distribution and Sales Area Table 32. Global Rare Neurodegenerative Disease Treatment Manufacturers Market Concentration Ratio (CR5 and HHI) Table 33. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Rare Neurodegenerative Disease Treatment as of 2020 Table 34. Date of Key Manufacturers Enter into Rare Neurodegenerative Disease Treatment Market Table 35. Key Manufacturers Rare Neurodegenerative Disease Treatment Product Type Table 36. Mergers & Acquisitions, Expansion Plans Table 37. Global Rare Neurodegenerative Disease Treatment Market Size Comparison by Region (US$ Million): 2016 VS 2021 VS 2027 Table 38. Global Rare Neurodegenerative Disease Treatment Sales by Region (2016-2021) & (K Units) Table 39. Global Rare Neurodegenerative Disease Treatment Sales Market Share in Volume by Region (2016-2021) Table 40. Global Rare Neurodegenerative Disease Treatment Sales by Region (2016-2021) & (US$ Million) Table 41. Global Rare Neurodegenerative Disease Treatment Sales Market Share in Value by Region (2016-2021) Table 42. Global Rare Neurodegenerative Disease Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021) Table 43. Global Rare Neurodegenerative Disease Treatment Sales by Region (2022-2027) & (K Units) Table 44. Global Rare Neurodegenerative Disease Treatment Sales Market Share in Volume by Region (2022-2027) Table 45. Global Rare Neurodegenerative Disease Treatment Sales by Region (2022-2027) & (US$ Million) Table 46. Global Rare Neurodegenerative Disease Treatment Sales Market Share in Value by Region (2022-2027) Table 47. Global Rare Neurodegenerative Disease Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2022-2027) Table 48. Global Rare Neurodegenerative Disease Treatment Sales by Application: 2016 VS 2021 VS 2027 (US$ Million) Table 49. Global Rare Neurodegenerative Disease Treatment Sales by Application (2016-2021) & (K Units) Table 50. Global Rare Neurodegenerative Disease Treatment Sales Market Share in Volume by Application (2016-2021) Table 51. Global Rare Neurodegenerative Disease Treatment Sales by Application (2016-2021) & (US$ Million) Table 52. Global Rare Neurodegenerative Disease Treatment Sales Market Share in Value by Application (2016-2021) Table 53. Global Rare Neurodegenerative Disease Treatment Price by Application (2016-2021) & (US$/Unit) Table 54. Global Rare Neurodegenerative Disease Treatment Sales by Application (2022-2027) & (K Units) Table 55. Global Rare Neurodegenerative Disease Treatment Sales Market Share in Volume by Application (2022-2027) Table 56. Global Rare Neurodegenerative Disease Treatment Sales by Application (2022-2027) & (US$ Million) Table 57. Global Rare Neurodegenerative Disease Treatment Sales Market Share in Value by Application (2022-2027) Table 58. Global Rare Neurodegenerative Disease Treatment Price by Application (2022-2027) & (US$/Unit) Table 59. North America Rare Neurodegenerative Disease Treatment Sales by Application (2016-2021) (K Units) Table 60. North America Rare Neurodegenerative Disease Treatment Sales by Application (2016-2021) & (US$ Million) Table 61. North America Rare Neurodegenerative Disease Treatment Sales Market Share in Value by Application in 2020 Table 62. Europe Rare Neurodegenerative Disease Treatment Sales by Application (2016-2021) (K Units) Table 63. Europe Rare Neurodegenerative Disease Treatment Sales by Application (2016-2021) & (US$ Million) Table 64. Europe Rare Neurodegenerative Disease Treatment Sales Market Share in Value by Application in 2020 Table 65. Asia-Pacific Rare Neurodegenerative Disease Treatment Sales by Application (2016-2021) (K Units) Table 66. Asia-Pacific Rare Neurodegenerative Disease Treatment Sales by Application (2016-2021) & (US$ Million) Table 67. Asia-Pacific Rare Neurodegenerative Disease Treatment Sales Market Share in Value by Application in 2020 Table 68. Latin America Rare Neurodegenerative Disease Treatment Sales by Application (2016-2021) (K Units) Table 69. Latin America Rare Neurodegenerative Disease Treatment Sales by Application (2016-2021) & (US$ Million) Table 70. Latin America Rare Neurodegenerative Disease Treatment Sales Market Share in Value by Application in 2020 Table 71. Middle East and Africa Rare Neurodegenerative Disease Treatment Sales by Application (2016-2021) (K Units) Table 72. Middle East and Africa Rare Neurodegenerative Disease Treatment Sales by Application (2016-2021) & (US$ Million) Table 73. Middle East and Africa Rare Neurodegenerative Disease Treatment Sales Market Share in Value by Application in 2020 Table 74. North America Rare Neurodegenerative Disease Treatment Sales by Country (2016-2021) & (K Units) Table 75. North America Rare Neurodegenerative Disease Treatment Sales Market Share in Volume by Country (2016-2021) Table 76. North America Rare Neurodegenerative Disease Treatment Sales by Country (2016-2021) & (US$ Million) Table 77. North America Rare Neurodegenerative Disease Treatment Sales Market Share in Value by Country (2016-2021) Table 78. North America Rare Neurodegenerative Disease Treatment Sales by Country (2022-2027) & (K Units) Table 79. North America Rare Neurodegenerative Disease Treatment Sales Market Share in Volume by Country (2022-2027) Table 80. North America Rare Neurodegenerative Disease Treatment Sales by Country (2022-2027) & (US$ Million) Table 81. North America Rare Neurodegenerative Disease Treatment Sales Market Share in Value by Country (2022-2027) Table 82. Europe Rare Neurodegenerative Disease Treatment Sales by Country (2016-2021) & (K Units) Table 83. Europe Rare Neurodegenerative Disease Treatment Sales Market Share in Volume by Country (2016-2021) Table 84. Europe Rare Neurodegenerative Disease Treatment Sales by Country (2016-2021) & (US$ Million) Table 85. Europe Rare Neurodegenerative Disease Treatment Sales Market Share in Value by Country (2016-2021) Table 86. Europe Rare Neurodegenerative Disease Treatment Sales by Country (2022-2027) & (K Units) Table 87. Europe Rare Neurodegenerative Disease Treatment Sales Market Share in Volume by Country (2022-2027) Table 88. Europe Rare Neurodegenerative Disease Treatment Sales by Country (2022-2027) & (US$ Million) Table 89. Europe Rare Neurodegenerative Disease Treatment Sales Market Share in Value by Country (2022-2027) Table 90. Asia-Pacific Rare Neurodegenerative Disease Treatment Sales by Region (2016-2021) & (K Units) Table 91. Asia-Pacific Rare Neurodegenerative Disease Treatment Sales Market Share in Volume by Region (2016-2021) Table 92. Asia-Pacific Rare Neurodegenerative Disease Treatment Sales by Region (2016-2021) & (US$ Million) Table 93. Asia-Pacific Rare Neurodegenerative Disease Treatment Sales Market Share in Value by Region (2016-2021) Table 94. Asia-Pacific Rare Neurodegenerative Disease Treatment Sales by Region (2022-2027) & (K Units) Table 95. Asia-Pacific Rare Neurodegenerative Disease Treatment Sales Market Share in Volume by Region (2022-2027) Table 96. Asia-Pacific Rare Neurodegenerative Disease Treatment Sales by Region (2022-2027) & (US$ Million) Table 97. Asia-Pacific Rare Neurodegenerative Disease Treatment Sales Market Share in Value by Region (2022-2027) Table 98. Latin America Rare Neurodegenerative Disease Treatment Sales by Country (2016-2021) & (K Units) Table 99. Latin America Rare Neurodegenerative Disease Treatment Sales Market Share in Volume by Country (2016-2021) Table 100. Latin America Rare Neurodegenerative Disease Treatment Sales by Country (2016-2021) & (US$ Million) Table 101. Latin America Rare Neurodegenerative Disease Treatment Sales Market Share in Value by Country (2016-2021) Table 102. Latin America Rare Neurodegenerative Disease Treatment Sales by Country (2022-2027) & (K Units) Table 103. Latin America Rare Neurodegenerative Disease Treatment Sales Market Share in Volume by Country (2022-2027) Table 104. Latin America Rare Neurodegenerative Disease Treatment Sales by Country (2022-2027) & (US$ Million) Table 105. Latin America Rare Neurodegenerative Disease Treatment Sales Market Share in Value by Country (2022-2027) Table 106. Middle East and Africa Rare Neurodegenerative Disease Treatment Sales by Country (2016-2021) & (K Units) Table 107. Middle East and Africa Rare Neurodegenerative Disease Treatment Sales Market Share in Volume by Country (2016-2021) Table 108. Middle East and Africa Rare Neurodegenerative Disease Treatment Sales by Country (2016-2021) & (US$ Million) Table 109. Middle East and Africa Rare Neurodegenerative Disease Treatment Sales Market Share in Value by Country (2016-2021) Table 110. Middle East and Africa Rare Neurodegenerative Disease Treatment Sales by Country (2022-2027) & (K Units) Table 111. Middle East and Africa Rare Neurodegenerative Disease Treatment Sales Market Share in Volume by Country (2022-2027) Table 112. Middle East and Africa Rare Neurodegenerative Disease Treatment Sales by Country (2022-2027) & (US$ Million) Table 113. Middle East and Africa Rare Neurodegenerative Disease Treatment Sales Market Share in Value by Country (2022-2027) Table 114. Bayer Corporation Information Table 115. Bayer Introduction and Business Overview Table 116. Bayer Rare Neurodegenerative Disease Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021) Table 117. Bayer Rare Neurodegenerative Disease Treatment Product Table 118. Bayer Recent Development Table 119. GlaxoSmithKline Corporation Information Table 120. GlaxoSmithKline Introduction and Business Overview Table 121. GlaxoSmithKline Rare Neurodegenerative Disease Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021) Table 122. GlaxoSmithKline Rare Neurodegenerative Disease Treatment Product Table 123. GlaxoSmithKline Recent Development Table 124. Hoffmann-La Roche Corporation Information Table 125. Hoffmann-La Roche Introduction and Business Overview Table 126. Hoffmann-La Roche Rare Neurodegenerative Disease Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021) Table 127. Hoffmann-La Roche Rare Neurodegenerative Disease Treatment Product Table 128. Hoffmann-La Roche Recent Development Table 129. Allergan Corporation Information Table 130. Allergan Introduction and Business Overview Table 131. Allergan Rare Neurodegenerative Disease Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021) Table 132. Allergan Rare Neurodegenerative Disease Treatment Product Table 133. Allergan Recent Development Table 134. Merck KGaA Corporation Information Table 135. Merck KGaA Introduction and Business Overview Table 136. Merck KGaA Rare Neurodegenerative Disease Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021) Table 137. Merck KGaA Rare Neurodegenerative Disease Treatment Product Table 138. Merck KGaA Recent Development Table 139. Johnson and Johnson Corporation Information Table 140. Johnson and Johnson Introduction and Business Overview Table 141. Johnson and Johnson Rare Neurodegenerative Disease Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021) Table 142. Johnson and Johnson Rare Neurodegenerative Disease Treatment Product Table 143. Johnson and Johnson Recent Development Table 144. Pfizer Corporation Information Table 145. Pfizer Introduction and Business Overview Table 146. Pfizer Rare Neurodegenerative Disease Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021) Table 147. Pfizer Rare Neurodegenerative Disease Treatment Product Table 148. Pfizer Recent Development Table 149. Novartis Corporation Information Table 150. Novartis Introduction and Business Overview Table 151. Novartis Rare Neurodegenerative Disease Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021) Table 152. Novartis Rare Neurodegenerative Disease Treatment Product Table 153. Novartis Recent Development Table 154. Sanofi Corporation Information Table 155. Sanofi Introduction and Business Overview Table 156. Sanofi Rare Neurodegenerative Disease Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021) Table 157. Sanofi Rare Neurodegenerative Disease Treatment Product Table 158. Sanofi Recent Development Table 159. Teva Pharmaceuticals Corporation Information Table 160. Teva Pharmaceuticals Introduction and Business Overview Table 161. Teva Pharmaceuticals Rare Neurodegenerative Disease Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021) Table 162. Teva Pharmaceuticals Rare Neurodegenerative Disease Treatment Product Table 163. Teva Pharmaceuticals Recent Development Table 164. Key Raw Materials Lists Table 165. Raw Materials Key Suppliers Lists Table 166. Rare Neurodegenerative Disease Treatment Market Trends Table 167. Rare Neurodegenerative Disease Treatment Market Drivers Table 168. Rare Neurodegenerative Disease Treatment Market Challenges Table 169. Rare Neurodegenerative Disease Treatment Market Restraints Table 170. Rare Neurodegenerative Disease Treatment Distributors List Table 171. Rare Neurodegenerative Disease Treatment Downstream Customers Table 172. Research Programs/Design for This Report Table 173. Key Data Information from Secondary Sources Table 174. Key Data Information from Primary Sources List of Figures Figure 1. Rare Neurodegenerative Disease Treatment Product Picture Figure 2. Global Rare Neurodegenerative Disease Treatment Market Size, 2016 VS 2021 VS 2027 (US$ Million) Figure 3. Global Rare Neurodegenerative Disease Treatment Market Size Status and Outlook (2016-2027) & (US$ Million) Figure 4. Global Rare Neurodegenerative Disease Treatment Sales Status and Outlook (2016-2027) & (K Units) Figure 5. Product Picture of Neurotransmitter Agents Figure 6. Global Neurotransmitter Agents Sales YoY Growth (2016-2021) & (K Units) Figure 7. Product Picture of Neuroprotective Agents Figure 8. Global Neuroprotective Agents Sales YoY Growth (2016-2021) & (K Units) Figure 9. Product Picture of Biologics Figure 10. Global Biologics Sales YoY Growth (2016-2021) & (K Units) Figure 11. Product Picture of Others Figure 12. Global Others Sales YoY Growth (2016-2021) & (K Units) Figure 13. Global Rare Neurodegenerative Disease Treatment Sales by Type (2016-2027) & (US$ Million) Figure 14. Global Rare Neurodegenerative Disease Treatment Sales Market Share in Volume by Type (2016-2021) Figure 15. Global Rare Neurodegenerative Disease Treatment Sales Market Share in Value by Type (2016-2021) Figure 16. Global Rare Neurodegenerative Disease Treatment Sales Market Share in Volume by Type (2022-2027) Figure 17. Global Rare Neurodegenerative Disease Treatment Sales Market Share in Value by Type (2022-2027) Figure 18. North America Rare Neurodegenerative Disease Treatment Sales Market Share in Volume by Type in 2020 Figure 19. North America Rare Neurodegenerative Disease Treatment Sales Market Share in Value by Type in 2020 Figure 20. Europe Rare Neurodegenerative Disease Treatment Sales Market Share in Volume by Type in 2020 Figure 21. Europe Rare Neurodegenerative Disease Treatment Sales Market Share in Value by Type in 2020 Figure 22. Asia-Pacific Rare Neurodegenerative Disease Treatment Sales Market Share in Volume by Type in 2020 Figure 23. Asia-Pacific Rare Neurodegenerative Disease Treatment Sales Market Share in Value by Type in 2020 Figure 24. Latin America Rare Neurodegenerative Disease Treatment Sales Market Share in Volume by Type in 2020 Figure 25. Latin America Rare Neurodegenerative Disease Treatment Sales Market Share in Value by Type in 2020 Figure 26. Middle East and Africa Rare Neurodegenerative Disease Treatment Sales Market Share in Volume by Type in 2020 Figure 27. Middle East and Africa Rare Neurodegenerative Disease Treatment Sales Market Share in Value by Type in 2020 Figure 28. The 5 and 10 Largest Manufacturers in the World: Market Share by Rare Neurodegenerative Disease Treatment Sales in 2020 Figure 29. The 5 and 10 Largest Manufacturers in the World: Market Share by Rare Neurodegenerative Disease Treatment Revenue in 2020 Figure 30. Rare Neurodegenerative Disease Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2016 VS 2020 Figure 31. Product Picture of Amyotrophic Lateral Sclerosis (ALS) Figure 32. Global Amyotrophic Lateral Sclerosis (ALS) Sales YoY Growth (2016-2027) & (K Units) Figure 33. Product Picture of Attention Deficit Hyperactivity Disorder (ADHD) Figure 34. Global Attention Deficit Hyperactivity Disorder (ADHD) Sales YoY Growth (2016-2027) & (K Units) Figure 35. Product Picture of Alzheimer’s Disease Figure 36. Global Alzheimer’s Disease Sales YoY Growth (2016-2027) & (K Units) Figure 37. Product Picture of Parkinson’s Disease Figure 38. Global Parkinson’s Disease Sales YoY Growth (2016-2027) & (K Units) Figure 39. Product Picture of Others Figure 40. Global Others Sales YoY Growth (2016-2027) & (K Units) Figure 41. Global Rare Neurodegenerative Disease Treatment Sales by Application (2016-2027) & (US$ Million) Figure 42. Global Rare Neurodegenerative Disease Treatment Sales Market Share in Volume by Application (2016-2021) Figure 43. Global Rare Neurodegenerative Disease Treatment Sales Market Share in Value by Application (2016-2021) Figure 44. Global Rare Neurodegenerative Disease Treatment Sales Market Share in Volume by Application (2022-2027) Figure 45. North America Rare Neurodegenerative Disease Treatment Sales Market Share in Volume by Application in 2020 Figure 46. Latin America Rare Neurodegenerative Disease Treatment Sales Market Share in Value by Application in 2020 Figure 47. Middle East and Africa Rare Neurodegenerative Disease Treatment Sales Market Share in Value by Application in 2020 Figure 48. Key Raw Materials Price Figure 49. Rare Neurodegenerative Disease Treatment Manufacturing Cost Structure Figure 50. Rare Neurodegenerative Disease Treatment Industrial Chain Analysis Figure 51. Channels of Distribution Figure 52. Distributors Profiles Figure 53. Bottom-up and Top-down Approaches for This Report Figure 54. Data Triangulation Figure 55. Key Executives Interviewed

Bayer GlaxoSmithKline Hoffmann-La Roche Allergan Merck KGaA Johnson and Johnson Pfizer Novartis Sanofi Teva Pharmaceuticals